sars cov-2

SARS-CoV-2-IN-38 is an orally available SARS-CoV-2 inhibitor with potential antiviral activity for the study of SARS viral infections.

SARS-CoV-2 Mpro-IN-2 is a selective SARS-CoV-2M pro inhibitor with an IC50 value of 0.40 μM.SARS-CoV-2 Mpro-IN-2 has good antiviral activity and can be used to study COVID-19.

SARS-CoV-2 Mpro-IN-9 (compound c7), a nonpeptidic, noncovalent inhibitor of SARS-CoV-2 main protease (Mpro), exhibits potent inhibitory action (IC50 = 0.085 μM) and improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. It effectively suppresses viral replication in SARS-CoV-2-infected Vero E6 cells (EC50 = 1.10 μM) and demonstrates low cytotoxicity (CC50 > 50 μM) [1].

SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor of SARS-CoV-2 3CLpro activity, exerting its effect by forming a covalent bond with Cys145.

SARS-CoV-2-IN-14 is a potent and oral inhibitor of SARS-CoV-2 (IC50:0.39 μM), which is an analogue of niclosamide. SARS-CoV-2-IN-14 was more stable than niclosamide in the determination of human plasma and liver S9 enzyme. Oral administration of SARS-CoV-2-IN-14 can improve its bioavailability and half-life.

SARS-CoV-2-IN-46, a SARS-CoV-2 inhibitor, is [2-({[(5-nitrofuran-2-yl)methylidene]amino}oxy)-N-(pyrimidin-2-yl)acetamide].

SARS-CoV-2-IN-39 is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 has antiviral activity and inhibits SARS-CoV-2 by inhibiting SKP2 protein and stabilizing BECN1.

SARS-CoV-2-IN-1 is a potent inhibitor of Mpro [SARS-CoV-2 Mpro, SARS-CoV Mpro, and MERS-CoV Mpro] with IC50 values of 0.67, 0.90, and 0.58 μM, respectively.

SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication.

SARS-CoV-2 3CLpro-IN-25 (compound 56) effectively inhibits the SARS-CoV-2 3CLpro enzyme, exhibiting an IC50 value of 70 nM, and demonstrates cellular antiviral activity with an EC50 of 3.1 μM.

SARS-CoV-2-IN-99 (compound 58) is an inhibitor of the main protease of SARS-CoV-2.

SARS-CoV-2-IN-97 (Compound CO-01) is an inhibitor of the SARS-CoV-2Nsp15 endoribonuclease, exhibiting an IC50 of 53.5 μM. It demonstrates low cytotoxicity in A549-AT cells with an IC50 value of 134 μM.

SARS-CoV-2-IN-98 (compound 38) is a SARS-CoV-2 inhibitor with a dissociation constant (Kd) of 0.73 μM, utilized in research on COVID-19.

SARS-CoV-2 Mpro-IN-25 (Compound 3a) is a protease inhibitor for SARS-CoV-2, exhibiting an IC50 value of 0.26 μM. It demonstrates antiviral activity and is useful for research in the field of pneumonia.

SARS-CoV-2-IN-96 (compound 12b) acts as an inhibitor for both HCoV-OC43 (EC50= 97 nM) and SARS-CoV-2 (EC50= 45 nM), while displaying low cytotoxicity in Huh7 cells (CC50=10 μM).

SARS-CoV-2 Mpro-IN-26 (compound 13) is a covalent inhibitor targeting SARS-CoV-2 Mpro.

SARS-CoV-2 Mpro-IN-27 (Compound 4h) is an effective inhibitor of SARS-CoV-2 Mpro.

SARS-CoV-2 Mpro-IN-31 (Compound 18) is an inhibitor of SARS-CoV-2 MPro with an IC50 of 11 nM. Additionally, this compound effectively inhibits the enzymatic activity of the cysteine proteases cathepsin B and cathepsin L, with IC50 values of 24 nM and 1.8 nM, respectively.

SARS-CoV-2-IN-100 (Compound 172) is a broad-spectrum antiviral agent against various SARS-CoV-2 variants. It works synergistically with Nirmatrelvir to reduce the risk of antiviral resistance.

SARS-CoV-2 3CLpro-IN-27 (Compound 9H) is an inhibitor of SARS-CoV-2 3CLpro, demonstrating an IC50 of 21 nM. It also exhibits robust anti-replicase activity against SARS-CoV-2, with an EC50 of 5 nM.

SARS-CoV-2-IN-102 (example 58) is an inhibitor of the SARS-CoV papain-like protease (SARS-CoVPLpro), demonstrating an IC50 of less than 100 nM.

SARS-CoV-2 Mpro-IN-32 (Compound 1) is a selective inhibitor of SARS-CoV-2 MPro with an IC50 value of 230 nM. In vitro, it also inhibits the replication of various SARS-CoV-2 variants.

SARS-CoV-2 Mpro-IN-28 (Compound 1K) is an inhibitor of SARS-CoV-2 Mpro, exhibiting an EC50 of 24 μM.

SARS-CoV-2-IN-101 (compound 10O) is an effective orally active inhibitor of SARS-CoV-2 with an EC50 value of 0.64 µM against HCoV-229E. This compound exhibits cytotoxicity and can reduce the expression levels of HCoV-229E N protein and RNA. Additionally, SARS-CoV-2-IN-101 has broad-spectrum antiviral activity against coronaviruses.